AEZS News Alert Aeterna Zentaris (AEZS) 0.55 11/18/2014 20:3

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 9:32 PM

Aeterna Zentaris (AEZS) 0.55 $AEZS

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aeterna Zentaris, Inc. to Contact Brower Piven Before the January 12, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- AEZS
GlobeNewswire - Tue Nov 18, 1:35PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company"

(Nasdaq:AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period"

. Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
AEZS: 0.55 (unch)

Notice of Filing of Securities Fraud Class Action against Aeterna Zentaris Inc. by Abraham, Fruchter & Twersky, LLP
Business Wire - Mon Nov 17, 9:33AM CST
Abraham, Fruchter & Twersky, LLP has filed a securities fraud class action against Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company"

(NASDAQ:AEZS) and certain of its senior executives in the United States District Court for the District of New Jersey (the "Court"

.
AEZS: 0.55 (unch)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aeterna Zentaris, Inc. - AEZS
PR Newswire - Fri Nov 14, 12:46PM CST
Pomerantz LLP is investigating claims on behalf of investors of Aeterna Zentaris, Inc. ("Aeterna" or the "Company"

(NASDAQ: AEZS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
AEZS: 0.55 (unch)

EQUITY ALERT: The Rosen Law Firm Files Securities Fraud Class Action Against Aeterna Zentaris, Inc. -- AEZS
GlobeNewswire - Tue Nov 11, 8:23PM CST
The Rosen Law Firm announces that it has filed a class action lawsuit on behalf of purchasers of Aeterna Zentaris, Inc. (Nasdaq:AEZS) securities between October 18, 2012 and November 6, 2014. The lawsuit seeks to recover damages for Aeterna Zentaris investors under the federal securities laws.
AEZS: 0.55 (unch)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Aeterna Zentaris Inc. (AEZS) To Contact The Firm
PR Newswire - Tue Nov 11, 4:15PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Aeterna Zentaris Inc. ("Aeterna" or the "Company"

(NASDAQ: AEZS).
AEZS: 0.55 (unch)

INVESTOR ALERT: Investigation of Aeterna Zentaris, Inc. Announced by Glancy Binkow & Goldberg LLP
Business Wire - Mon Nov 10, 9:32AM CST
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company"

(NASDAQ:AEZS) concerning possible violations of federal securities laws. The investigation is focused on the Company's operations and financial prospects.
AEZS: 0.55 (unch)

Why I Still Remain Bearish On AEterna Zentaris
Daniel Ward - at Seeking Alpha - Sat Nov 08, 7:21AM CST

AEZS: 0.55 (unch)

SHAREHOLDER ALERT: Investigation on Behalf of Aeterna Zentaris, Inc. Investors Announced by Law Offices of Howard G. Smith
Business Wire - Fri Nov 07, 4:08PM CST
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company"

(NASDAQ:AEZS). The investigation concerns possible violations of federal securities laws and focuses on certain statements issued by Aeterna Zentaris concerning the Company's operations and business prospects.
AEZS: 0.55 (unch)

Downgrade Alert for AEterna Zentaris (AEZS)
Comtex SmarTrend(R) - Fri Nov 07, 6:53AM CST
AEterna Zentaris (NASDAQ:AEZS) was downgraded from Buy to Neutral at H.C. Wainwright today. The stock closed yesterday at $0.65 on volume of 22.8 million shares, above average daily volume of 1.6 million. In the past 52 weeks, shares of AEterna Zentaris have traded between a low of $0.57 and a high of $1.74 and closed yesterday at $0.65, which is 14% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.6% while the 200-day MA has slid 0.5%.
AEZS: 0.55 (unch)

The Rosen Law Firm Announces Investigation of Securities Claims Against Aeterna Zentaris, Inc.
Business Wire - Thu Nov 06, 6:02PM CST
The Rosen Law Firm announces that it is investigating potential securities fraud claims against Aeterna Zentaris, Inc. (NASDAQ:AEZS) resulting from its announcement that the FDA would not approve its New Drug Application ("NDA"

.
AEZS: 0.55 (unch)

Midday Gainers/Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:47AM CST

SWIR: 39.32 (+0.67), PERI: 5.62 (-0.15), RMGN: 1.32 (+0.10), WWWW: 16.77 (+0.21), ASTI: 1.82 (+0.07), GNW: 9.36 (+0.03), SNMX: 5.34 (+0.18), ALXA: 1.50 (+0.02), PLUS: 68.44 (+0.09), PPO: 52.49 (-0.03), NSM: 27.82 (-0.50), AEZS: 0.55 (unch), WAC: 16.80 (+0.27), KATE: 28.99 (+0.26), CGG: 8.60 (+0.08), ANDE: 54.48 (+0.28), ENG: 1.93 (+0.03), PLNR: 7.39 (+0.34), ALG: 45.51 (+0.56), SZYM: 3.21 (-0.23)

Aeterna Zentaris slammed after FDA rejection
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:42AM CST

AEZS: 0.55 (unch)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:14AM CST

ACAS: 14.87 (-0.12), WWWW: 16.77 (+0.21), PHMD: 2.21 (-0.08), RVLT: 1.53 (unch), SNMX: 5.34 (+0.18), PBR: 9.42 (+0.09), QCOM: 72.01 (+1.61), GNRC: 43.83 (+1.95), HZNP: 12.85 (+0.35), PESI: 4.39 (unch), WAC: 16.80 (+0.27), TRUE: 17.42 (-0.18), KATE: 28.99 (+0.26), DRYS: 1.43 (+0.02), Z: 118.96 (+1.10), WFM: 47.89 (+0.48), SWIR: 39.32 (+0.67), COT: 6.69 (-0.19), CSOD: 30.57 (+0.36), MCP: 1.20 (-0.06), GNW: 9.36 (+0.03), CECO: 5.54 (-0.05), GERN: 3.17 (+0.19), NDLS: 22.65 (-0.22), MEET: 1.80 (-0.01), AEZS: 0.55 (unch), DATA: 82.10 (-1.21), PLNR: 7.39 (+0.34), SZYM: 3.21 (-0.23)

FDA Issues Complete Response Letter for Aeterna Zentaris' Macrilen™ NDA in Adult Growth Hormone Deficiency
PR Newswire - Thu Nov 06, 6:00AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"

today announced that the Company has received a Complete Response Letter ("CRL"

from the U.S. Food and Drug Administration ("FDA"

for its New Drug Application ("NDA"

for MacrilenTM (macimorelin), a novel orally-active ghrelin agonist, for use in evaluating adult growth hormone deficiency ("AGHD"

. Based on its review, the FDA has determined that the NDA cannot be approved in its present form.
AEZ.TO: 0.63 (-0.01), AEZS: 0.55 (unch)

Update: AEterna Zentaris Q3 2014 Earnings
Samreen Agha - at Seeking Alpha - Thu Nov 06, 3:58AM CST

AEZS: 0.55 (unch)

Aeterna Zentaris' (AEZS) CEO David Dodd on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 5:30PM CST

AEZS: 0.55 (unch)

IIROC Trading Halt - AEX
CNW Group - Wed Nov 05, 2:52PM CST
The following issues have been halted by IIROC:
AEX.VN: 0.110 (unch), AEZS: 0.55 (unch)

PDUFA date today for Aeterna's macimorelin acetate
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 11:02AM CST

AEZS: 0.55 (unch)

AEterna Zentaris Up 11.7%, Shares Break Through Resistance (AEZS)
Comtex SmarTrend(R) - Wed Nov 05, 10:06AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 11.7% to $1.24 on 3.1x average daily volume. Thus far today, AEterna Zentaris has traded 4.3 million shares, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (11.7% to the Dow's 0.4%) and outperformed the S&P 500 (11.7% to the S&P's 0.4%) during today's trading.
AEZS: 0.55 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

ASTS Faces Crucial Deadline Amidst Legal Turmoil

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Quest Diagnostics Faces Class Action After Data Breach

Data Breach Rocks Quest Diagnostics October 2026 caught Quest Diagnostics in a bind they wish they could escape—a classic tech breach with personal info hanging out to dry. When a cyber ghost slipped into Quest's Quanum Lab Services Manager, it wasn't to deliver flowers. Nope, this unauthorized access was no friendly visit, forcing Quest to scream foul and play serious...

Millrose Faces Securities Fraud Suit Amidst Decline

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

John Wong's Decade as Estate Planning Specialist

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

DIRECTV Bags New NHL Deals: Stakes for Sports Fans

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

SLM Faces Legal Scrutiny as Losses Mount Amid Pause

SLM's Latest Troubles: Legal and Financial Impact Ah, student loans—not just a headache for borrowers but now for lenders too. SLM Corporation, that name we know all too well in the student debt circus, has hit a snag. They've paused most of their third-party recovery activities. Let's dig in: net charge-offs for SLM in the third quarter shot up to a hefty $90.4...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Lilly's Sofe-M Shakes Up Ovarian Cancer Treatment

Ovarian Cancer Treatment Sees a New Challenger Alright, folks, Eli Lilly (NYSE:LLY) is stepping up with their latest findings in ovarian cancer treatment, and it's got plenty of people in a buzz. They've dropped new data for their investigational drug, Sofetabart mipitecan, or 'Sofe-M' for short, which targets this unrelenting disease with a punch that’s hard to ignore....

Tony Perkins' Church Tour amid Controversial Vote

Lining the pews in Missouri and Kansas, folks are about to get a powerful dose of Tony Perkins this weekend. The Family Research Council President is driving straight into the heart of both spiritual and political fervor at a couple of church stops on Sunday, October 25—right on the doorstep of a crucial vote in Missouri. Taking the Stage in a Time of Tension Now,...